What a discouraging waiting period !I think after the phase 2 test, if the result is positively well enough the company can apply for FDA approval. In that case it will seal the success of the drug. Again if it turns out the drug is useless, we will run for cover. So my fellow shareholders, it is just a game of patience and hope. I wish within this waiting period some other biotectch companys will come along and show some interest on Shigamab or the still alive 4601.
By the way is 4601 dead yet or we still have a revising opportunity ? Mind you 4601 was our flagship hoepeful and I still strongly believe there is something there yet to
explore. Please keep posing, we have to keep this board alive. Have a merry Christmas to all posters and readers.